Abstract
Comutations on pCGP in EGFRm NSCLC. A, Mutational landscape of EGFRm NSCLC in pCGP. Landscape figures represent the distribution of mutations among patients with EGFRm NSCLC, with findings clustered according to the number of previous lines of therapy. Each column represents an iteration of pCGP, and genes are clustered in rows according to the cellular pathway affected. Clinical metadata are represented in rows at the top of the diagram. The feature “EGFR activating” reflects EGFR mutations detected on pCGP assays. Several patients did not have EGFR mutations identified on pCGP but were included in this set as they were known to harbor EGFR activating mutations based on prior tissue NGS. We noted an early emergence of pathogenic alterations in genes in the PI3K pathway, late emergence of genomic alterations in the RAS pathway, and frequent cell-cycle gene alterations across settings. B–E, Key comutations in patients with EGFRm NSCLC by line of therapy. Pie–donut charts reflect the prevalence of EGFR comutations by the number of previous lines of TKI therapy. The inner circle in each chart reflects the cancer hallmark and gene families affected. The outer circle describes the individual genes altered. MET alterations are seen with increased frequency with later lines of therapy, whereas PI3K group alterations—predominantly PTEN mutations—become less frequent. DDR, DNA damage response.